| This week's sponsor is CRF Bracket. | |  | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Friday, May 24, 2019 After 19 salespeople resigned from Amgen last year to join Karyopharm, which is preparing to launch a rival multiple myeloma drug, Amgen sued, alleging theft of trade secrets. Now, as it awaits an FDA decision on its multiple myeloma drug selinexor, Karyopharm is fighting to get the suit thrown out. |
|
|
Top Stories Of The Week Tuesday, May 28, 2019 Just before Memorial Day weekend, five biotech companies dropped their initial public offering plans, adding up to $611 million in anticipated cash. Wednesday, May 29, 2019 Novartis has lost its head of oncology and lead for its global head, cell and gene therapy unit Pascal Touchon as he steps up to become the CEO and president of California biotech Atara Biotherapeutics. Tuesday, May 28, 2019 The FDA has approved a new diagnostic tool to help determine whether swelling around a prosthetic joint replacement is being caused by an infection. Friday, May 24, 2019 Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma—and just how payers would cover the "transformative" spinal muscular atrophy treatment. Now, they have their answers. Tuesday, May 28, 2019 Novartis’ promise of 25 potential blockbuster launches is steadily coming to fruition. On the same day the FDA approved gene therapy Zolgensma, the U.S. regulator also waved through breast cancer drug Piqray. Tuesday, May 28, 2019 AstraZeneca is set to prioritize the treatment of early-stage cancers under the leadership of oncology research chief José Baselga, M.D., Ph.D. Talking to The Wall Street Journal, Baselga sketched out why he thinks splitting off from the congested pursuit of late-stage cancers will benefit AstraZeneca and patients. Monday, May 27, 2019 The CRISPR-Cas9 gene editing system has been hailed as a promising solution to a range of genetic diseases, but the technology has proven difficult to deliver into cells. Scientists at Fred Hutchinson Cancer Research Center developed gold nanoparticles that can deliver CRISPR to mouse models of HIV and inherited blood disorders. Wednesday, May 29, 2019 Bristol-Myers Squibb is losing another key commercial cog, and this time Gilead's the culprit. The Big Biotech poached Johanna Mercier, who led the U.S., Germany, France and Japan for BMS, to serve as its next commercial chief. And behind the scenes, it gave ex-CCO Laura Hamill a $1.75 million cash goodbye. Wednesday, May 29, 2019 In a transcontinental move, a California biotech working on a cell therapy for solid tumors will build its first manufacturing site in Philadelphia. Resources Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Sponsored by: Catalent Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: AlphaSense What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve? Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. |
|
